Latest Content

Ryan Last, senior associate at Troutman Pepper Locke, details the key steps that pharma companies must make before the July 31st deadline hits.

A U.S. House committee has launched national security investigations into Merck, AbbVie, Eli Lilly, Pfizer, and Bristol Myers Squibb over their clinical trial operations in China, seeking answers by July 17 on data protection, military hospital ties, and trial sites in Xinjiang.

FDA selected seven companies to participate in its new PreCheck Pilot Program, offering earlier regulatory engagement and expedited facility review to incentivize domestic drug manufacturing.

In today's Pharmaceutical Executive Daily, a pharma M&A roundup covers Ipsen's up to $1.75 billion acquisition of Kartos Therapeutics and Zymeworks' $929 million acquisition of Theravance Biopharma, Krista Pinto of Eversana argues that fully staffed pharma field teams are still missing revenue targets because the traditional deployment model itself needs to evolve, and EMA's CHMP issues a positive opinion recommending approval of Eli Lilly's Jaypirca for chronic lymphocytic leukemia across all lines of therapy in the European Union.

Zymeworks and Ipsen each announced acquisitions this week, with Zymeworks paying roughly $929 million for Theravance Biopharma to gain commercial COPD royalties and tax assets, and Ipsen committing up to $1.75 billion for Kartos Therapeutics to add navtemadlin.

Krista Pinto, EVERSANA’s president of deployment solutions, shares her perspective on why traditional field team models need to evolve to support future commercial success.

The decision was made based on the results of the BRUIN CLL-313 clinical study.

Healthspan is merging from obscure academic jargon as a potent consumer driver, reshaping how people think about aging and redefining pharma’s role in that process.

New data from ADA 2026 reveal that assumptions around age, weight, and gestational history are leaving too many T1D patients misclassified — and the clinical consequences are preventable.

Jeff Talbot of Roseman University of Health Sciences discusses how Las Vegas is positioning itself as a growing life sciences hub by offering cost-effective laboratory space, access to capital, and a flexible environment for biotech startups and emerging companies.

Novartis will fund Antares’ development of first-in-class precision medicines in cancer and other serious diseases.

Once a niche pilot, direct-to-patient drug distribution is now a defining strategic priority, with manufacturers building the right infrastructure standing to capture margin, data, and patient relationships that used to belong to intermediaries.

Aprecia’s president and COO discusses the impact 3D printing technology is having on drug development, along with the benefits and challenges of being a company that is 100-percent US-based for its manufacturing.